SMH
TCRT icon

Sanders Morris Harris’s Alaunos Therapeutics TCRT Stock Holding History

Sanders Morris Harris’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,341
Closed -$930K – 204
2020
Q1 		$930K Hold
1,341
– – 0.91% 30
2019
Q4 		$930K Buy
+1,341
New +$923K 0.21% 118

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sanders Morris Harris's TCRT Position: Q2 2020 in Review

Sanders Morris Harris sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 1,341 shares — an estimated $930K sold.

Sanders Morris Harris first reported a position in TCRT in Q4 2019 and held it in 2 quarters. The position peaked at $930K in Q1 2020. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

  • Sanders Morris Harris reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Sanders Morris Harris sold 1,341 Alaunos Therapeutics shares in Q2 2020, an estimated $930K.
  • Sanders Morris Harris first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 2 quarters.
  • Sanders Morris Harris's Alaunos Therapeutics position peaked at $930K in Q1 2020.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on Sanders Morris Harris's 13F filing for Q2 2020, filed 9 Jul 2020.